T1	Treatment 22 47	gonadotropin combinations
T2	Treatment 140 182	human recombinant FSH/human recombinant LH
T3	Treatment 202 247	highly purified human menopausal gonadotropin
T4	Treatment 560 624	human recombinant FSH (r-hFSH) plus human recombinant LH (r-hLH)
T5	Treatment 645 715	highly purified human menopausal gonadotropin (hMG-HP) urinary extract
T6	Treatment 912 930	150 IU hMG-HP (150
T7	Treatment 988 1010	150IU r-hFSH/75IU rhLH
T8	Treatment 1125 1148	hMG-HP or r-hFSH/r-hLH.
T9	Treatment 1507 1526	70% of r-hFSH/r-hLH
T10	Treatment 1572 1578	88% in
T11	Treatment 1611 1629	PR in r-hFSH/r-hLH
T12	Treatment 1658 1673	23.3% in hMG-HP
T13	Treatment 1787 1798	superiority
T14	Treatment 1805 1816	compared to
T15	Treatment 1824 1834	supporting
